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Background. We identified child-related determinants of health-related quality of life (HRQoL) in children aged 8–14 years who were
treated for 2 common types of pediatric brain tumors.
Methods. Questionnaire measures of HRQoL and psychometric assessments were completed by 110 children on 3 occasions over 24
months. Of these 110, 72 were within 3 years of diagnosis of a cerebellar tumor (37 standard-risk medulloblastoma, 35 low-grade
cerebellar astrocytoma), and 38 were in a nontumor group. HRQoL, executive function, health status, and behavioral difficulties were
also assessed by parents and teachers as appropriate. Regression modeling was used to relate HRQoL z scores to age, sex, socioeco-
nomic status, and 5 domains of functioning: Cognition, Emotion, Social, Motor and Sensory, and Behavior.
Results. HRQoL z scores were significantly lower after astrocytoma than those in the nontumor group and significantly lower again in
the medulloblastoma group, both by self-report and by parent-report. In regression modeling, significant child-related predictors of
poorer HRQoL z scores by self-report were poorer cognitive and emotional function (both z scores) and greater age (years) at enroll-
ment (B¼ 0.038, 0.098, 0.136, respectively). By parent-report, poorer cognitive, emotional and motor or sensory function (z score)
were predictive of lower subsequent HRQoL of the child (B¼ 0.043, 0.112, 0.019, respectively), while age at enrollment was not.
Conclusions. Early screening of cognitive and emotional function in this age group, which are potentially amenable to change, could
identify those at risk of poor HRQoL and provide a rational basis for interventions to improve HRQoL.
Keywords: cerebellar astrocytoma, children, medulloblastoma, outcome, quality of life.
A quarter of all childhood tumors develop in the brain, and 60% of
these arise in the posterior fossa.1 About half of long-term survi-
vors of childhood brain tumors have moderate or severe disabil-
ity,2,3 experience chronic medical conditions and significant
neurocognitive impairment,4,5 achieve significantly lower educa-
tional attainment than the general population,6 and suffer
long-term socioeconomic disadvantage7 including disadvantage
in the work place8 and impaired health-related quality of life
(HRQoL).9,10 Early identification of factors predicting impaired
HRQoLwould enable rehabilitation of these patients to be started
early and reduce their risk of subsequent impaired HRQoL.
Poorer HRQoL has been associated with factors such as low
IQ11,12 and poor social,9 physical,13,14 behavioral,11 and emotion-
al functioning.14 Previous studies of HRQoL in survivors have,
however, had methodological limitations. Cross-sectional studies
have been unable to explore the developmental trajectory of out-
come,15 while longitudinal studies have often been rendered in-
conclusive by high rates of attrition.11,16 Comparison groups
have usually not been representative of children in the general
population because they were selected from siblings or friends.17
Furthermore, heterogeneity of the study population has limited
separation of the multiple factors that may influence HRQoL
such as tumor location, type of surgical and adjuvant treat-
ment,11,18 age at diagnosis and assessment, time from diagnosis,
and sex,3,12 especially in single-center studies.
Finally, many previous studies have described tumor-related
factors that are not amenable to change. The diagnosis of
a brain tumor cannot be undone to improve HRQoL, and the
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potential benefit of varying tumor treatments on HRQoL (eg, by
dose reduction in chemotherapy and/or radiotherapy) is some-
thing that can only be assessed reliably in a multicenter, con-
trolled treatment trial that has little or no room for variation in
the individual patient except for response to acute toxicity. The
well-known associations between brain tumors and their treat-
ments on the one hand and HRQoL on the other hand, therefore,
lend themselves only to description of the child’s predicament
and/or the design of trials for the evaluation of antitumor
treatments.
Child-related factors associated with variation in HRQoL
scores, whether or not caused by the tumor or its treatment,
are potentially amenable to change by interventions targeted
at the specific cognitive, social, physical, behavioral, or emotional
function of the individual patient or at parental mental health,
whichmay affect both the child’s HRQoL and the parental percep-
tions of it.19,20
The present study describes the level and trajectory of HRQoL
scores in children diagnosed with low-grade cerebellar astrocyto-
ma or medulloblastoma (the 2 most common types of posterior
fossa tumor) who are old enough to report their own HRQoL reli-
ably. The former is usually treated with surgery alone, with
7-year survival as high as 100% in some reports,21 while the latter
requires adjuvant treatment with chemotherapy and radiotherapy.
Standard-risk medulloblastoma, with ,1.5 cm3 of residual tumor
and no evidence ofmetastatic spread, was reported to have a 78%
7-year survival in the most recently undertaken European trial.22
The aim of the study was to identify child-related factors, po-
tentially modifiable by intervention in the individual patient, and
to avoid the limitations of previous studies. Our strategy in this
study was therefore to use variables related to the tumor and
its treatment only for the purpose of description before proceed-
ing further to identify child-related predictive factors in both
tumor and nontumor groups, irrespective of their association
with tumor-related factors.
Materials and Methods
Design
A multicenter prospective longitudinal study was undertaken
from February 2005 to January 2010.
Patients
Children aged 8–14 years with either “standard-risk” medullo-
blastoma (ie, ,1.5 cm3 residual tumor and no evidence of meta-
static disease) or low-grade cerebellar astrocytoma diagnosed
within the preceding 3 years were recruited from 11 of the 20
Children’s Cancer and Leukemia Group (CCLG) Children’s Cancer
Treatment Centers (CCTCs) in England and Wales over a period
of 20 months and then studied prospectively for a 24-month pe-
riod ending in 2010. These centers are the only hospitals provid-
ing this type of treatment in the UK. The completeness of the
cohort of cases enrolled in the present study was measured by
expressing the number of cases enrolled per year as a percentage
of the annual rate of diagnosis in all children fulfilling the study
inclusion criteria (whether or not offered to the study) and treated
at the 11 participating CCTCs over the most recently available
3-year period (1999–2001 data from the UK National Registry
of Childhood Tumors, kindly provided by C Stiller, Childhood Can-
cer Research Group, Oxford) and assuming a 1.3% subsequent
annual increase in the rate of diagnosis.23 The nontumor group
was randomly selected from the same year groups of the schools
attended by children in the tumor groups. Noninclusion criteria in
all groups were premorbid disability or inability to communicate
in the English language, but these criteria were not met in any
child referred to the study.
All participating children diagnosed with cerebellar tumor had
undergone neurosurgical removal of the tumor. Those with me-
dulloblastoma also received adjuvant treatment comprising 6
weeks of daily craniospinal radiotherapy of 23.4 Gy with a boost
of 55.8 Gy to the posterior fossa and Packer regimen chemother-
apy (weekly vincristine for 8 weeks followed 6 weeks later by eight
6-week cycles of chemotherapy consisting of CCNU and cisplatin
plus vincristine, given weekly for 3 weeks).24 There were no major
deviations from this standard treatment.
Measures
The primary outcome was the child’s HRQoL, reported by the chil-
dren and their parents using the Pediatric Quality of Life Inventory
(PedsQL),25 which was selected due to its good psychometric
properties, brevity,26,27 and applicability to both ill and healthy
populations10,18,28. Other assessments were undertaken as
follows: cognitive functioning, assessed using the Wechsler Intel-
ligence Scale for Children-4th UK Edition (WISC-IV UK);29 parent-
and teacher-report of the child’s executive function in everyday
life using the Behavior Rating Inventory of Executive Function
(BRIEF);30 parent- and child-report of the child’s health status
using the Health Utilities Index (HUI3);31 parent-, teacher-, and
child-report of the child’s behavior using the Strengths and Diffi-
culties Questionnaire (SDQ);32 and parent-report of their own psy-
chological well-being using the General Health Questionnaire
(GHQ-12).33 Baseline information obtained from parents included
premorbid socioeconomic status (SES) based on the UK Office of
National Statistics Socio-economic Classification (ONS 2004). In-
formation on clinical neurological status before and after tumor
excision was provided by treatment centers.
Procedure
Children fulfilling inclusion criteria were identified from hospital
discharge and clinic lists and referred to the study center by the
treating clinicians. Written informed consent was obtained from
all participating parents and children. Three assessments were
undertaken in the family home, to which questionnaires were
sent by post in advance, while the WISC was administered at
the visit itself. Parents were given comprehensive instructions by
phone prior to the visit regarding how they should provide assis-
tance to their child, if the need arose, without influencing their re-
sponses to the items. The first of the 3 visits was within the first
month after recruitment (T1), with subsequent visits at 12 and 24
months thereafter (T2 and T3). For each home visit, teacher ques-
tionnaires were also completed. The protocol for this study was
approved by the UK CCLG. Ethical approval was obtained from
the Trent Multi-centre Research Ethics Committee, UK.
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Statistical Analyses
The power calculation was based on a predicted sample of 90
children at the third year follow-up: a sample size of 3×30 chil-
dren could detect a difference in HRQoL between each of the 3
groups of 0.74 standard deviations (SDs) with an 80% power at
P, .05 in a 2 sided t test. Sample size calculations for prediction
models are not so easily performed since the required sample size
depends on the intercorrelation between factors (unknown in ad-
vance) as well as the actual effect sizes being estimated. Howev-
er, since adding variables into a multiple linear regression model
decreases the overall standard error, the overall power was not
reduced in modeling.
The group mean and SD PedsQL scores in the nontumor group
were used to derive z scores for the participants surviving brain
tumors where the mean and SD in the nontumor group was 0
and 1, respectively. In other words, the z scores in the participants
treated for brain tumors were expressed in terms of the number
of SDs from the mean in the nontumor group. Intergroup differ-
ences in PedsQL z scores were calculated, and time changes in
HRQoL within groups and comparisons between groups were an-
alyzed using 2-way ANOVA to enable group effects and time
trends to be determined independently.
The model for child-related factors predicting HRQoL was then
built using data from “complete-cases” (ie, participants in whom
both child- and parent-reported HRQoL scores were available at
all 3 time points). WISC subscale scores and child-, parent-, and
teacher- reports of subscales from the HUI (not teacher-report),
SDQ, and BRIEF (not child report) were assigned, according to
their content, to 5 theoretically derived domains of function:
Emotion, Behavior, Social, Motor and Sensory, and Cognition
(see Appendix A). Internal consistency for each domain of func-
tioning was established using Cronbach’s alpha. The mean of the
sum of the constituent subscale z scores constituted the score for
each domain, with all domains scored in the direction of higher
scores indicating worse function. Forced entry and backwards
stepwise multiple regression analyses were conducted to identify
predictors measured at T1 that were associated with child- and
parent-reported HRQoL scores at T3, 24 months later.
Predictors entered into the first step of the model were SES,
sex, and child’s age. Time from tumor diagnosis was not included
because it was not associated with HRQoL in the 2 tumor groups
considered separately or together in simple linear regression. Pre-
dictors that appeared to bemore important (P, .1) were retained
for the second step, in which parental mental health and the 5
domains of child-functioning were added to the model and
those with stronger (P, .1) associations with HRQoL retained.
The regression analysis was then rerun until only predictors for
which P, .1 remained to provide the final predictive model. All
tests were conducted using IBM SPSS version 19.0. All other sig-
nificance values were at the level of P, .05, 2-tailed.
Results
Study Sample
Seventy-six children surviving cerebellar tumors were referred to
the study center. Of these, 72 (95%), comprising 37 with medul-
loblastoma and 35 with astrocytoma, were enrolled into the
study at a mean (range) time interval from tumor diagnosis of
15.5 months (range,1–35 months) (Table 1). The annual rate of
Table 1. Child and parent characteristics at enrollment into study
Medullo n¼ 37 Astro n¼ 35 No Tumor n¼ 38
Mean age in years (range) 10.2 (8–14) 10.4 (8–14) 10.4 (8–14)
Mean age in years at diagnosis (range) 8.8 (6–13) 9.2 (5–14) N/A
Mean months from diagnosis (range) 16.2 (1–35) 14.7 (1–35) N/A
Respondent mean age in years (SD) 39.4 (5.5) 41.0 (8.1) 40.5 (5.3)
n (%) n (%) n (%)
Female 16 (43) 23 (66) 19 (50)
Mother respondent 35 (95) 32 (91) 33 (87)
Single-parent family 8 (22) 3 (9) 5 (13)
Only child 9 (25) 3 (9) 4 (11)
Parent education
None 1 (3) 2 (6) 2 (5)
School 14 (38) 5 (14) 7 (18)
College 15 (42) 18 (51) 21 (55)
University 6 (16) 10 (29) 8 (21)
Unknown 1 (3) 0 0
SES prediagnosis
Managerial/professional 11 (31) 22 (63) 18 (47)
Intermediate 14 (39) 8 (23) 7 (18)
Routine and manual 7 (19) 5 (14) 10 (26)
Not working 4 (11) 0 3 (8)
Unknown 1 (3) 0 0
Abbreviations: astro, low-grade cerebellar astrocytoma; medullo, standard-risk medulloblastoma; N/A, not applicable; no tumor, nontumor comparison
group; SD, standard deviation; SES, socioeconomic status.
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enrollment into the study over the 1.84-year recruitment period
was 95% of the estimated (see methods) number of diagnoses
of eligible cases at participating centers over that time (number
recruited per year/expected number of eligible patients: 20.4/
19.6 [104%] for medulloblastoma; 18.8/21.7 [87%] for astrocyto-
ma). Seven of the 72 (10%) tumor survivors became ineligible for
inclusion in the analysis because the child had a tumor relapse (5
medulloblastomas, 2 astrocytomas) during the study, leaving 65
in the study. Of the 38 participants in the nontumor comparison
group (seemethods), 25 were the first random choice, and 7 were
the second random choice, the first family having declined to par-
ticipate. Attrition due to withdrawal from the study (ie, without
tumor relapse) occurred in 7 of 65 (11%) of the tumor survivors
(3 medulloblastoma, 4 astrocytoma) and in 2 of 38 (5%) cases in
the nontumor group. Child and parent demographic characteris-
tics were similar in the 3 groups at recruitment except for an ex-
cess of single parents, only children, lower parental educational
qualifications, and occupations other than managerial or profes-
sional in families of children surviving medulloblastoma (Table 1).
The mean number of adverse clinical neurological features per
child increased over the perioperative period from 4.1 to 5.7 for
children with medulloblastoma and from 2.7 to 2.9 for those
with astrocytoma. Only 4 of 37 (11%) participants with medullo-
blastoma and 12 of 35 (34%) with astrocytoma had no adverse
postoperative clinical features (Table 2). Fifteen (41%) of the me-
dulloblastoma group had not yet completed adjuvant treatment
at T1, but mean HRQoL scores between those on and off treat-
ment at T1 were very similar and are therefore shown collapsed
into a single group.
Mean HRQoL scores in the whole study sample of 103 partici-
pants at T1 were similar to those in the group of 90 complete
cases that was used to compare groups and to identify predictors
of HRQoL at T3. Both SES and the functional consequences of ad-
verse neurological features, reflected in Health Status subscores
(allocated to the Emotion, Behavior, Social, Motor and Sensory
function, and Cognitive domains of function, as appropriate)
were included in the regression modeling.
HRQoL Scores Over Time by Tumor Diagnosis
Mean child-reported PedsQL z scores hardly changed over the
whole time period in any of the 3 groups (Fig. 1), increasing by
only 0.08 SDs (P¼ .70). Mean parent-reported PedsQL z scores in-
creased over the 24-month study period by 0.33 SDs (Fig. 1), but
this change was not significant after adjusting for group (P¼ .18).
Compared with those of children in the nontumor group, mean
(95% CI) HRQoL z scores, adjusted for time, were lower in the me-
dulloblastoma and astrocytoma groups both by child report
(22.03 [21.64 to 22.43]; 21.04 [20.65 to 21.43] respectively,
P always ,.001) and by parent-report (23.32 [22.84 to 23.80];
21.58 [21.11 to 22.05] respectively, P always ,.001). The per-
centage of children whose PedsQL total scale score (on a scale
of 0–100) fell in the category of being “at risk of impaired
HRQoL”26 was greatest in the medulloblastoma group (score
,69.7 by self-report in 73%; score ,65.4 by parent-report in
85%), intermediate in the astrocytoma group, and lowest in the
nontumor group (Fig. 1). The percentage of children at risk of
impaired HRQoL fell progressively over time in both tumor groups,
although remaining higher than in the nontumor group (Fig. 1).
Child Characteristics Predicting HRQoL
All the derived domains of functioning had good internal consis-
tency with Cronbach’s alpha coefficients of .0.7 (Appendix 1).
Domain scores (derived from subscale scores on measures
other than HRQoL; see Methods) for Emotion, Behavior, Social,
Motor and Sensory, and Cognition showed that function on
these domains was best in the nontumor comparison group, in-
termediate in the astrocytoma group, and worst in the medullo-
blastoma group. The domains of Cognition and Motor and
Sensory function showed the biggest absolute difference in
domain scores from the nontumor comparison group and also
showed the largest changes over the 24 months of the study:
this indicated a decrement in cognition function over time and
an improvement in motor and sensory function (Table 3). SES,
Table 2. Clinical neurological features before and after tumor resection
Medulloblastoma n¼ 37 Cerebellar Astrocytoma n¼ 35
Preresection n (%) Postresection n (%) Preresection n (%) Postresection n (%)
Severe hydrocephalus 17 (46) 4 (11) 12 (34) 4 (11)
Visual impairment 7 (19) 9 (24) 6 (17) 4 (11)
Speech impairment 3 (8) 11 (30) 1 (3) 6 (17)
Upper limb ataxia 19 (51) 19 (51) 12 (34) 9 (26)
Truncal ataxia 23 (62) 24 (65) 7 (20) 8 (23)
Limb weakness 1 (3) 12 (32) 2 (6) 5 (14)
Balance impairment 24 (65) 27 (73) 17 (49) 9 (26)
Walking impairment 15 (41) 18 (49) 11 (31) 10 (29)
Seizures 0 0 2 (6) 0
Cerebellar mutism 0 12 (32) 0 4 (11)
CNS/other infection 0 8 (22) 0 5 (14)
No adverse features 5 (14) 4 (11) 7 (20) 12 (34)
Mean no. of clinical features (SD) 4.1 (2.8) 5.7 (4.1) 2.7 (2.2) 2.9 (3.2)
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child’s sex, and child’s age were included in the first step of the
regression analyses, but none of these predictors remained signif-
icant as the modeling progressed. After inclusion of the 5 do-
mains of functioning in the regression model, cognitive
function, emotional function (both z scores) and greater age
(years) at enrollment at T1 predicted child-reported HRQoL at
T3 (B¼ 0.037, 0.100, 0.136, respectively), accounting for 53%
of the variance (Table 4). Cognitive function, emotional function,
and motor and sensory function (z score) at T1 were predictive of
subsequent HRQoL of the child by parent-report at T3 (B¼ 0.043,
0.112, 0.019 respectively) and accounted for 65% of the variance,
while age at enrollment was not (Table 5).
Discussion
Groupmean HRQoL scores of children aged 8–14 years, whowere
measured within the first 3 years after diagnosis of standard-risk
medulloblastoma or low-grade cerebellar astrocytoma, were per-
sistently significantly poorer than those of their contemporaries in
the same schools, with the deficit in HRQoL being greater after
treatment for medulloblastoma. The very high percentage of chil-
dren treated for medulloblastoma with “at risk” HRQoL scores at
the end of the 3-year study period emphasizes the very poor ini-
tial HRQoL seen in this group. Cognitive and emotional functions
were the most powerful child-related characteristics predicting
child- and parent-reported HRQoL scores 2 years later, both in
these children and in their contemporaries without tumors.
Other factors predicting subsequent HRQoL scores were greater
age at the first assessment by child self-report and motor and
sensory function of the child by parent/proxy report.
The findings in this study provide a rationale for screening of
cognitive and emotional function with selected questionnaires,
such as the ones used in our study, to identify those potentially
modifiable child-related characteristics that identify children likely
to be at risk for poor subsequent HRQoL. This could be undertaken
Fig. 1. Quality of Life Inventory mean total scores reported by 90 children and their parents over 24 months. Complete cases (ie, data from participants
and their parents at all 3 time points) in 3 groups: standard-risk medulloblastoma (n¼ 26), low-grade cerebellar astrocytoma (n¼ 28), and a nontumor
comparison group (n¼ 36). PedsQL¼Quality of Life Inventory25; Times 1, 2, and 3 were at enrollment, 12 months, and 24 months later, respectively.
Higher scores¼ better functioning. Error bars indicate 95% confidence intervals for the mean. Numbers adjacent to graphs show percentages of
children in each group at risk of impaired HRQoL26 (see text) at the 3 time points.
Table 3. Mean (standard deviation) domains of function z scores for all
available data at each time point in the 110 study participants
Domain of
Function
Mean Domain z Scores in All Participants*
At Enrollment
(T1)
At 12 Months
(T2)
At 24 Months
(T3)
Emotion
Medullo 4.03 (4.94) 5.89 (6.10) 3.86 (4.77)
Astro 1.64 (4.01) 3.30 (5.54) 2.57 (4.60)
Comparison 0.06 (3.15) 20.02 (2.91) 20.27 (3.35)
Behavior
Medullo 0.74 (3.87) 1.69 (4.18) 3.20 (5. 04)
Astro 1.24 (4.00) 2.20 (4.12) 3.64 (6.57)
Comparison 0.10 (4.26) 20.30 (3.87) 20.04 (4.68)
Social
Medullo 2.20 (4.33) 1.56 (4.57) 5.04 (6.58)
Astro 0.77 (3.34) 0.64 (4.32) 2.03 (4.82)
Comparison 0.05 (3.96) 20.02 (3.78) 20.18 (3.70)
Motor and sensory
Medullo 27.16 (27.31) 20.34 (26.25) 9.21 (13.88)
Astro 11.82 (25.04) 5.37 (15.04) 3.08 (12.17)
Comparison 0.00 (3.48) 0.00 (4.63) 0.00 (4.06)
Cognition
Medullo 14.41 (20.68) 17.53 (19.90) 25.14 (19.59)
Astro 10.25 (19.43) 13.93 (21.49) 17.19 (22.13)
Comparison 0.17 (14.03) 20.46 (13.19) 0.05 (13.24)
In all domains, higher score¼worse function. See methods for derivation
of domain scores.
Abbreviations: Astro¼ low-grade cerebellar astrocytoma; Comparison¼
nontumor comparison group; Medullo¼ standard-risk medulloblastoma
*Mean domain z scores are large in the tumor groups due to lack of
variation in the Comparison group.
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annually in clinics using brief, easily administered tools.34,35 Those
falling above or below the published cut of scores indicating clin-
ical risk could then undergo a full rehabilitation assessment and
be considered for early intervention.
The study incorporated 5 key methodological strengths. First,
the age range was designed to include only children old enough
to report reliably on their HRQoL36 and young enough for pediatric
HRQoL and other assessments to remain valid through the dura-
tion of the study. Second, families were assessed at all 3 time
points in more than 90% of recurrence-free participants, so that
attrition bias was avoided. Third, a nontumor group of compara-
ble age and educational background was selected in such a way
as to be representative of families unaffected by a history of a
tumor. Fourth, the inclusion criteria restricted the focus to survi-
vors of tumors in a single brain region, the cerebellum. Fifth, the
inclusion of 270 assessments in 90 participants in the longitudi-
nal modeling makes this an unusually large study of a sample
with such restrictive inclusion criteria.
The studywas powered to showmoderate-effect sizes between
groups, and the predictive model appeared able to identify those
factors exerting substantial predictive power. Regression models
containing a small number of factors appropriate to the sample
size, such as the final models presented in this paper, would
have high power to detect amoderately sized effect (seeMethods),
but small effects would not be detected andmight bemissed (type
II error). Other, less influential predictors might therefore have ap-
peared in a model generated by an even larger study.
Both the homogeneity of our sample and the importance of
the influence of the identified predictors on subsequent HRQoL
are supported by the large proportion of variance in HRQoL for
which they accounted. By using a range of measures and infor-
mants (eg, both parent- and teacher-report of executive function,
parent- and child-report of cognition, and direct assessment of
cognitive domains), we increased the sensitivity of the model to
several aspects of function in both home and school settings. The
subsequent conversion of scores to z scores and assignment to
underlying domains of function (eg, Cognition) minimized the
problem of multiple statistical testing. For all these reasons, we
believe that the findings are robust. Since the referral base for
this study included half of all children’s cancer treatment centers
in the UK and the number enrolled into the study was 95% of the
number of eligible cases expected over the recruitment period,
the findings are likely to be generalizable to all 8–14 year old
UK children with a recent diagnosis of cerebellar tumor. Indeed,
the percentage of those at risk for impaired of HRQoL aftermedul-
loblastoma in the present study (58% by self-report at T3) is very
similar to what we reported following conventionally fractionated
radiotherapy plus chemotherapy in PNET4 survivors across Eu-
rope, who were diagnosed at a similar mean age (8.9 years)
but over a wider age range (3–21 years) and assessed after a lon-
ger interval (7.2 years).37
Conversely, the restricted age category and tumor location
limit our ability to generalize the findings to other age groups or
tumor locations. In younger children and higher risk groups than
Table 4. Factors at study entry predicting quality of life: child-report 24
months later
B 95% CI for B P
Step 1 n¼ 92, R2¼ 0.126, R2adj¼ 0.075, P¼ .038
*SES intermediate 20.322 21.128 to 0.485 .430
*SES routine and manual 20.938 21.824 to 20.052 .038
*SES not in work 21.575 22.867 to 20.282 .018
Child’s sex (0¼ female, 1¼male) 0.108 20.562 to 0.777 .750
Child’s age (years) 20.189 20.369 to 20.009 .039
Step 2 n¼ 81, R2¼ 0.582, R2adj¼ 0.529, P, .001
*SES routine and manual 20.413 20.996 to 0.170 .162
*SES not in work 0.065 20.930 to 1.061 .896
Child’s age (years) 20.137 20.267 to 20.007 .039
Emotion z score 20.080 20.161 to 0.001 .053
Behavior z score 0.003 20.117 to 0.110 .951
Social z score 20.052 20.141 to 0.038 .253
Motor and sensory z score 20.010 20.022 to 0.003 .127
Cognition z score 20.024 20.048 to 20.001 .042
Caregiver mental health z score 20.030 20.258 to 0.199 .797
Final model n¼ 81, R2¼ 0.534, R2adj¼ 0.516, P, .001
Child’s age (years) 20.136 20.263 to 20.009 .036
Emotion z score 20.100 20.178 to 20.022 .013
Cognition z score 20.037 20.053 to 20.020 ,.001
*Socioeconomic status relative to the highest category (managerial and
professional).
Quality of Life scores were expressed as Pediatric Quality of Life Invento-
ry25 z scores (see methods).
Table 5. Factors at study entry predicting quality of life: parent-report 24
months later
B 95% CI for B P
Step 1 n¼ 94, R2¼ 0.091, R2adj¼ 0.039, P¼ .130
*SES intermediate 20.586 21.528 to 0.356 .220
*SES routine and manual 20.877 21.924 to 0.169 .099
*SES not in work 21.530 23.059 to 20.001 .050
Child’s sex (0¼ female, 1¼male) 20.183 20.964 to 0.599 .643
Child’s age (years) 20.194 20.407 to 0.018 .073
Step 2 n¼ 81, R2¼ 0.671, R2adj¼ 0.629, P, .001
*SES routine and manual 20.079 20.723 to 0.565 .807
*SES not in work 0.151 20.948 to 1.250 .785
Child’s age (years) 20.095 20.238 to 0.049 .192
Emotion z score 20.096 20.185 to -0.007 .036
Behavior z score 0.023 20.102 to 0.149 .711
Social z score 20.080 20.179 to 0.018 .108
Motor and sensory z score 20.016 20.029 to 20.002 .025
Cognition z score 20.038 20.064 to 20.012 .004
Caregiver mental health z score 20.126 20.378 to 0.126 .323
Final model N¼ 81, R2¼ 0.644, R2adj¼ 0.631, P, .001
Emotion z score 20.111 20.196 to 20.026 .011
Motor and sensory z score 20.019 20.032 to 20.006 .004
Cognition z score 20.043 20.063 to 20.023 ,.001
*Socioeconomic status relative to the highest category (managerial and
professional).
Quality of Life scores were expressed as Pediatric Quality of Life Invento-
ry25 z scores (see methods).
Bull et al.: Predictors of HRQOL in children with cerebellar tumors
6 of 9 Neuro-Oncology Practice
our study population, we would expect an even larger predictive
influence of cognition on HRQoL because the risk of deficits in pro-
cessing speed, attention, and working memory has long been
identified as increased in younger children and those with higher
risk status.38 However, children with poor neuropsychological
function sometimes assess their own HRQoL as being within the
range reported by typically developing children. The relationship
between age at diagnosis and HRQoL is further complicated by,
first, an increasing awareness of loss of previous abilities in chil-
dren who are older at diagnosis (perhaps accounting for the neg-
ative relationship between age and self-reported HRQoL in the
present study) and, second, a tendency for children (especially
girls) in their teens to report lower HRQoL than when assessed
earlier in childhood. Another study would therefore be needed
to test these predictions in younger children.
The upward trend in HRQoL self-report scores over time in the
nontumor group may reflect normal age-related pressures expe-
rienced by children such as the transition from primary to second-
ary school, which occurs in the UK in the lower part of the age
range of our sample.39 The use of HRQoL z scores calculated rel-
ative to those of the nontumor group at the same time point ad-
justed for this common social context. By contrast, the lack of
change over time in parent-report scores in the nontumor
group exemplifies the difference in the child and parent perspec-
tives, particularly with regard to less observable functioning.40
Further analysis of the differences between total scores and sub-
scores of parent-, teacher-, and self-report of the outcomes of
HRQoL, executive function, health status, and behavioral
strengths and difficulties in this study is in progress and will be
the subject of a further paper.
Earlier HRQoL scores are likely to correlate highly with subse-
quent HRQoL scores but were not included in our regression
model as potential predictors of subsequent HRQoL because
these scores represent the final consequences of underlying
child-related characteristics that we hope to change by interven-
tions; establishing that earlier HRQoL predicts subsequent HRQoL
would not have brought us closer to that goal. The fact that as-
sessments were done in the child’s home contributed to the high
retention rate. Any effects of the home setting onWISC scores are
likely to be small and similar in tumor and nontumor groups. They
should therefore not have biased intergroup comparisons and
were adjusted out of the predictive modeling by the use of z
scores that expressed scores in the tumor groups relative to the
range of scores in the nontumor group.
The dominant role, by both child- and parent-report, of cogni-
tive and emotional functioning in predicting subsequent HRQoL
and the finding that neither sex, nor parental occupation, nor pa-
rental mental health predicted HRQoL is consistent with some
previous reports relating to this age group.9,12,14,18,20 Other previ-
ous studies have reported discrepant findings that may be attrib-
utable to heterogeneity with respect to participant age, tumor
location, and interval from diagnosis or attrition bias.2,11,41,42
The importance to HRQoL of neurological deficit, the functional
consequences of which were captured in the motor and sensory
function domain, was reflected in the predictive role of that
domain by parent-report. The higher rate of neurological deficit,
including the presence of cerebellar mutism, as expected,43 in
one third in the medulloblastoma group is likely to have contrib-
uted to their poorer HRQoL and may reflect the more rapid pro-
gression of symptoms of hydrocephalus and other neurological
disorders44 in children with these more rapidly dividing tumors
compared with their progression rates in low-grade cerebellar as-
trocytomas. Their greater increase in these deficits between pre-
operative and postoperative assessments may be attributable to
their more midline location, less well-defined margins, and more
vigorous neurosurgical effort to improve survival rates by achiev-
ing complete resection.45
Current guidelines in the UK suggest that psychological assess-
ment of childhood brain tumor survivors should be undertaken
only when concerns about poor HRQoL are raised by teachers
or parents,6 and this problem is not confined to the UK.46 Identi-
fication of difficulties is therefore frequently late, but more timely
interventions could be informed by early screening. Specific rec-
ommendations for brief screening tests and batteries of tests
have been made and shown to be feasible in the context of clin-
ical trials across North America and Europe.47,48 Cognitive and
physical remediation programs have already shown promising re-
sults in the short and medium term to enhance academic
achievement in this age group, and social-skills training has
shown a benefit to HRQoL in preliminary studies of children treat-
ed for brain tumors.49–52 Sustainable low-cost interventions, such
as online peer-to-peer support networks,53 also need to be ex-
plored. The long-term benefit of early screening and the interven-
tion that might follow is, however, yet to be established.
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Appendix 1. Domains of function with constituent subscales and
internal consistency coefficients
Domain of
Function
Constituent Subscales Cronbach’s
Alpha
Emotion SDQ Emotional symptoms (P,C,T) 0.714
HUI3 Emotional level (P,C)
Behavior SDQ Conduct problems (P,C,T) 0.753
SDQ Hyperactivity and inattention (P,C,T)
Social SDQ Peer problems (P,C,T) 0.659
SDQ Prosocial behavior (P,C,T)
Motor and
sensory
HUI3 Vision level (P,C) 0.8
HUI3 Hearing level (P,C)
HUI3 Speech level (P,C)
HUI3 Ambulation level (P,C)
HUI3 Dexterity level (P,C)
HUI3 Pain level (P,C)
Cognition HUI3 Cognition level (P,C) 0.931
BRIEF Inhibit (P,T)
BRIEF Shift (P,T)
BRIEF Emotional control (P,T)
BRIEF Initiate (P,T)
BRIEF Working memory (P,T)
BRIEF Plan and organise (P,T)
BRIEF Organisation of materials (P,T)
BRIEF Monitor (P,T)
WISC Verbal (A)
WISC Perceptual reasoning (A)
WISC Working memory (A)
WISC Processing speed (A)
Cronbach’s alpha shown was calculated from subscale scores at
enrollment (ie, Time 1).
Abbreviations: A, direct assessment; BRIEF, Behavior Rating Inventory of
Executive Function; C, child-report; HUI3, Health Utilities Index; P,
parent-report, SDQ, Strengths and Difficulties Questionnaire; T, teacher-
report; WISC, Wechsler Intelligence Scale for Children.
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